Skip to main content
mediabuyer
← Spy index

Landing-page host dossier

Ads pointing to genomeweb.com

61 creatives · 7 advertisers · 1 network

Total ads

61

Advertisers

7

First seen

Apr 14

Last seen

May 11

Networks

mediabuyer.site indexes 61 native ad creatives whose landing page resolves to genomeweb.com. Those creatives are produced by 7 distinct advertisers and run across Outbrain (61). The geographic footprint includes QA (47), South Korea (32), Taiwan (32), Finland (22), Australia (11), Canada (6), Singapore (5), United States (1). Top verticals on this host: health, auto, general. Average creative longevity for this host is 11 days; the longest-running ad has been live for 26 days. The first ad pointing at genomeweb.com entered our index on Apr 14; the most recent on May 11. Use the gallery below to inspect every active creative, the headline patterns advertisers are testing, and the related landing pages that share the same advertiser base.

Top creatives

ranked by longevity

Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
mediabuyer
OutbrainOther
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
GenomeWeb | Sponsored@genomeweb
🇦🇺AU24d+6
genomeweb.com
Visit
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
mediabuyer
OutbrainOther
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
GenomeWeb | Sponsored@genomeweb
🇨🇦CA22d+3
genomeweb.com
Visit
Leukemia Trial to Assess DNA Methylation, Mutation Tests to Stratify Patients
mediabuyer
OutbrainOther
Leukemia Trial to Assess DNA Methylation, Mutation Tests to Stratify Patients
GenomeWeb | Sponsored@genomeweb
🇰🇷KR19d+2
genomeweb.com
Visit
Not Just for Kids Anymore: Diagnostic Whole-Genome Sequencing Reaches Adults
mediabuyer
OutbrainOther
Not Just for Kids Anymore: Diagnostic Whole-Genome Sequencing Reaches Adults
GenomeWeb | Sponsored@genomeweb
🇫🇮FI19d+1
genomeweb.com
Visit
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
mediabuyer
OutbrainOther
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
GenomeWeb | Sponsored@genomeweb
🇫🇮FI19d+2
genomeweb.com
Visit
Researchers Aim to Validate ERCC2 as Therapy-Response Biomarker in Bladder Cancer
mediabuyer
OutbrainOther
Researchers Aim to Validate ERCC2 as Therapy-Response Biomarker in Bladder Cancer
GenomeWeb | Sponsored@genomeweb
🇫🇮FI18d+2
genomeweb.com
Visit

Sample headlines

  • Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility×8
  • Heart Transplant Rejection Study Suggests Blood Test Adds Prognostic Insight Beyond Biopsy×5
  • Perspective: From Scale to Accessibility - Reengineering Genomic Sequencing Infrastructure×4
  • Users of Blood-Based MRD Testing for Solid Tumors Split on Approaches, Applications×4
  • Researchers Aim to Validate ERCC2 as Therapy-Response Biomarker in Bladder Cancer×3
  • Rapid Whole Genome Sequencing Enables Earlier Diagnoses for Infants with Cardiac Indications×3
  • Genetic Testing Driving Increase in Medicare Lab Spending, According to HHS OIG Report×3
  • Healthcare Implementation Study in Israel Finds Rapid Newborn Genome Sequencing Feasible, Beneficial×2
  • Labs, Doctors Still Grapple With Patient Recontact Despite Streamlined Variant Reclassification×2
  • Baylor Genetics’ Rapid WGS Enables Earlier Diagnoses for Infants with Cardiac Indications×2
  • New Multi-Cancer Detection Data Speak to Both Promises and Cautions of Blood-Based Assays×2
  • CMS Final Pricing for Genomic Procedure Codes Leaves Lab, Industry Stakeholders Wanting More×2

Top advertisers using genomeweb.com

Full gallery

every indexed ad

Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
mediabuyer
OutbrainOther
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
GenomeWeb | Sponsored@genomeweb
🇰🇷KR16d
genomeweb.com
Visit
Users of Blood-Based MRD Testing for Solid Tumors Split on Approaches, Applications
mediabuyer
OutbrainOther
Users of Blood-Based MRD Testing for Solid Tumors Split on Approaches, Applications
GenomeWeb | Sponsored@genomeweb
🇰🇷KR16d+1
genomeweb.com
Visit
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
mediabuyer
OutbrainOther
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
GenomeWeb | Sponsored@genomeweb
🇦🇺AU15d+3
genomeweb.com
Visit
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
mediabuyer
OutbrainOther
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
GenomeWeb | Sponsored@genomeweb
🇰🇷KR14d+1
genomeweb.com
Visit
Baylor Genetics’ Rapid WGS Enables Earlier Diagnoses for Infants with Cardiac Indications
mediabuyer
Playing the Long Game: At ACMG, Firms Tout Long-Read Offerings for Rare Disease Testing
mediabuyer
New Multi-Cancer Detection Data Speak to Both Promises and Cautions of Blood-Based Assays
mediabuyer
Adding Polygenic Risk Scores to Cardiovascular Disease Risk Tool May Improve Predictions
mediabuyer
Oncologists Contend With Practice Implications of Emerging Multi-Cancer Detection Tests
mediabuyer
Irish Project to Implement Genomic Sequencing in Pediatric Cancer Care
mediabuyer
Oncologists Contend With Practice Implications of Emerging Multi-Cancer Detection Tests
mediabuyer
Users of Blood-Based MRD Testing for Solid Tumors Split on Approaches, Applications
mediabuyer
Genetic Testing Driving Increase in Medicare Lab Spending, According to HHS OIG Report
mediabuyer
Genetic Testing Driving Increase in Medicare Lab Spending, According to HHS OIG Report
mediabuyer
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
mediabuyer
OutbrainOther
Perspective: Reengineering Genomic Sequencing Infrastructure for Accessibility
Promoted by GenomeWeb@promoted
🇫🇮FI5d+2
genomeweb.com
Visit
Genetic Testing Driving Increase in Medicare Lab Spending, According to HHS OIG Report
mediabuyer
Researchers Aim to Validate ERCC2 as Therapy-Response Biomarker in Bladder Cancer
mediabuyer
OutbrainOther
Researchers Aim to Validate ERCC2 as Therapy-Response Biomarker in Bladder Cancer
GenomeWeb | Sponsored@genomeweb
🇨🇦CA2d+1
genomeweb.com
Visit
Researchers Aim to Validate ERCC2 as Therapy-Response Biomarker in Bladder Cancer
mediabuyer
OutbrainOther
Researchers Aim to Validate ERCC2 as Therapy-Response Biomarker in Bladder Cancer
GenomeWeb | Sponsored@genomeweb
🇫🇮FI0d+1
genomeweb.com
Visit
Kentucky's St. Elizabeth Healthcare to Bring Pharmacogenomic Testing In-House
mediabuyer
OutbrainOther
Kentucky's St. Elizabeth Healthcare to Bring Pharmacogenomic Testing In-House
GenomeWeb | Sponsored@genomeweb
🇶🇦QA0d
genomeweb.com
Visit
Users of Blood-Based MRD Testing for Solid Tumors Split on Approaches, Applications
mediabuyer